Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nils Degrauwe"'
Autor:
Nils Degrauwe, Arnaud Hocquelet, Antonia Digklia, Niklaus Schaefer, Alban Denys, Rafael Duran
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
We are continuously progressing in our understanding of cancer and other diseases and learned how they can be heterogeneous among patients. Therefore, there is an increasing need for accurate characterization of diseases at the molecular level. In pa
Externí odkaz:
https://doaj.org/article/35d5ada4a45b47d7be844ed7f25c6e55
Autor:
Nils Degrauwe, Tommy B. Schlumpf, Michalina Janiszewska, Patricia Martin, Alexandra Cauderay, Paolo Provero, Nicolo Riggi, Mario-L. Suvà, Renato Paro, Ivan Stamenkovic
Publikováno v:
Cell Reports, Vol 15, Iss 8, Pp 1634-1647 (2016)
Cancer stem cells (CSCs) can drive tumor growth, and their maintenance may rely on post-transcriptional regulation of gene expression, including that mediated by microRNAs (miRNAs). The let-7 miRNA family has been shown to induce differentiation by s
Externí odkaz:
https://doaj.org/article/ade7b28da6e345d6b3b4ca6c55bd81c8
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2012, Iss 6, Pp 243-252 (2012)
Externí odkaz:
https://doaj.org/article/b63c0013fc904010961e29931d37be4e
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 61:270-272
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c82cdd645d64f3bed52dc40f3b88b677
https://doi.org/10.5414/cp204364
https://doi.org/10.5414/cp204364
Autor:
Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, Sabine Galland, Andrea Serena, Melissa Christofis, Nuria Mederos, Hasna Bouchaab, Antonella Diciolla, Nassim Dris, Angela Orcurto, Claire Perrinjaquet, Marc Schnetz, Sofiya Latifyan, Laureline Wetterwald, Ruth Gabriela Herrera Gómez, Valérie Cristina, Apostolos Sarivalasis, Olivier Michielin, Dominik Berthold, Antonia Digklia, Anna Dorothea Wagner, Khalil Zaman, Solange Peters, Athina Stravodimou
Publikováno v:
Revue Médicale Suisse. 19:52-57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b36853729eba92fe90735f2e731077a0
https://doi.org/10.53738/revmed.2023.19.809-10.52
https://doi.org/10.53738/revmed.2023.19.809-10.52
Autor:
Karim Abdelhamid, Artemisia Kakourou, Nils Degrauwe, Asteria Nikolopoulou, Hasna Bouchaab, Solange Peters, Tu Nguyen-Ngoc, Nuria Mederos
Publikováno v:
Revue Médicale Suisse. 16:1079-1085
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07236b06d508c340c84942fa3c79cc6e
https://doi.org/10.53738/revmed.2020.16.695.1079
https://doi.org/10.53738/revmed.2020.16.695.1079
Autor:
Nermin Halkic, Rafael Duran, Nils Degrauwe, Nicolas Demartines, Alban Denys, Emmanuel Melloul
Publikováno v:
Frontiers in Radiology, vol. 1
Purpose: Hepatic and/or portal vein embolization are performed before hepatectomy for patients with insufficient future liver remnant and usually achieved with a trans-hepatic approach. The aim of the present study is to describe a modified trans-ven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dac2a6550b0e538f42f2b14dcb5d81fc
https://doi.org/10.3389/fradi.2021.736056
https://doi.org/10.3389/fradi.2021.736056
Autor:
Karim, Abdelhamid, Artemisia, Kakourou, Nils, Degrauwe, Asteria, Nikolopoulou, Hasna, Bouchaab, Solange, Peters, Tu, Nguyen-Ngoc, Nuria, Mederos
Publikováno v:
Revue medicale suisse. 16(695)
Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of less than 20%. In the majority of cases, patients have metastatic disease at diagnosis despite the new screening method by low-dose CT-scan. The high throughput sequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::86263ace3f9a245c9143461b0e74a221
https://pubmed.ncbi.nlm.nih.gov/32462835
https://pubmed.ncbi.nlm.nih.gov/32462835
Publikováno v:
Arangalage, Dimitri; Degrauwe, Nils; Michielin, Olivier; Monney, Pierre; Özdemir, Berna C. (2021). Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer treatment reviews, 100, p. 102282. Elsevier 10.1016/j.ctrv.2021.102282
Immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi/MEKi) have drastically improved the outcome of melanoma patients. ICIs can induce myocarditis, a rare immune related adverse event (irAE) with an estimated lethality of 50%. BRAFi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9892dfccd949091520d5c77e05564722
https://doi.org/10.1016/j.ctrv.2021.102282
https://doi.org/10.1016/j.ctrv.2021.102282
Autor:
Niklaus Schaefer, Antonia Digklia, Nils Degrauwe, Rafael Duran, Arnaud Hocquelet, Alban Denys
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in Pharmacology
Frontiers in Pharmacology
We are continuously progressing in our understanding of cancer and other diseases and learned how they can be heterogeneous among patients. Therefore, there is an increasing need for accurate characterization of diseases at the molecular level. In pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21f69c1e36911895a3ed5326a2c7eb5